C4 Therapeutics Q1 net loss widens to $34.8M; cash runway into 2025

C4 Therapeutics, Inc.

2023-Q1 EPS reported -$0.71 revenue$3,759,000

Net loss of $34.8M ($0.71 per share) vs. $31.6M ($0.65) in Q1 2022; revenue dropped to $3.8M from $7.7M.
R&D expense rose to $29.0M (Q1 2022: $26.2M) driven by clinical trial costs for CFT7455, CFT8634, CFT1946.
Cash, equivalents and marketable securities were $305.0M as of March 31, 2023, expected to fund operations into 2025.
Phase 1 dose-escalation data for CFT7455 (monotherapy in multiple myeloma) and CFT8634 (synovial sarcoma) expected in H2 2023.
IND submission for CFT8919 (NSCLC) targeted for H1 2023; first patient dosed in CFT1946 Phase 1/2 trial in January.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

C4 Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $3.8 million, net income $34.8 million, EPS $0.71.

Period: the first quarter ended March 31, 2023
Revenue: $3.8 million
Net income: $34.8 million
EPS: $0.71
Result: reported results

Exact text from the filing

will participate in the Jefferies Global Healthcare Conference in New York. FIRST QUARTER 2023 FINANCIAL RESULTS Revenue: Total revenue for the first quarter of 2023 was $3.8 million, compared to $7.7 million for the first quarter of 2022. Total revenue reflects revenue recognized under collaboration agreements with Roche, Biogen, and Calico. Research and

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-015454

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.